Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy
AssigneeSeattle Children’s Hospital d/b/a Seattle Children’s Research Institute
InventorsGiacomo Tampella, Michael C. Jensen, Adam Johnson
Life of this patent
Estimating the term…
Abstract
Some embodiments of the methods and compositions provided herein include cells having membrane-tethered, IL13 mutein-directed zetakine receptors, such as those which specifically bind to the IL-13 receptor alpha 2 (IL13Ra2) at a 50-fold higher affinity than wildtype IL-13, and methods of cell-based immunotherapy targeting cancer cells, such as cells of solid tumors, using these compositions. In some embodiments, the receptors include spacer regions, such as particular spacer regions designed to provide certain advantages.
Claims25
A nucleic acid encoding a membrane-tethered IL-13 mutein-directed zetakine receptor, the zetakine receptor comprising:
- an extracellular domain comprising a mutein of IL-13 and a spacer;
- a transmembrane domain;
- and
- an intracellular signaling region,
- wherein the spacer is interposed between the mutein and transmembrane domain.
Dependencies are inferred from the claim text.